SCHEMBL20372808

SCHEMBL20372808

CCCCC(CCC)C1CCN(C(C)=O)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ DPP4 P27487 3/20 0.36
▸ DPP7 Q9UHL4 2/20 0.36
▸ GNAI3 P08754 3/20 0.36
▸ GNAO1 P09471 3/20 0.36
▸ GNAI1 P63096 3/20 0.36
▸ LMNA P02545 1/20 0.36
▸ PTBP1 P26599 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SIGMAR1 Q99720 1/20 0.36
▸ PIK3CD O00329 1/20 0.36
▸ EPHX2 P34913 2/20 0.36
▸ EPHX1 P07099 2/20 0.36
▸ CPN1 P15169 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21024634 0.92 GNAI3 (0.42) ALDH1A1KDM4EUSP2ALOX15GNAI3
SCHEMBL24040182 0.90 GNAI3 (0.43) ALDH1A1KDM4EUSP2ALOX15GNAI3
SCHEMBL24345186 0.87 GNAI3 (0.41) GNAI3GNAO1GNAI1EPHX2
SCHEMBL20626619 0.86 DPP4 (0.41) DPP4DPP7MAPTPIK3CDEPHX2
SCHEMBL22363328 0.81 PIK3CD (0.41) ALDH1A1KDM4EUSP2ALOX15DPP4
SCHEMBL11990125 0.78 PIK3CD (0.42) KDM4EDPP4DPP7MAPTPIK3CD
SCHEMBL24398569 0.77 GPR84 (0.41) MAPT
SCHEMBL22622606 0.77 PIK3CD (0.43) DPP4DPP7MAPTPIK3CDEPHX2
SCHEMBL13772773 0.77 GNAI3 (0.42) USP2DPP4GNAI3GNAO1GNAI1
SCHEMBL13772760 0.75 HPGD (0.45) ALDH1A1USP2DPP4MAPTEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10398706-B2 Heteroaryldiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2019-09-03 — — US disclosed
US-20180193352-A1 HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2018-07-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10398706-B2 Heteroaryldiazepine derivatives as RSV inhibitors CYP3A5, CYP3A43, CYP3A4 ALDH1A1 850/4885KDM4E 1045/4885USP2 4462/4885
US-20180193352-A1 HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS CYP3A5, CYP3A43, CYP3A4 ALDH1A1 850/4885KDM4E 1045/4885USP2 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback